생리활성 펩티드 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the bioactive peptides market size is projected to be USD 3.46 billion in 2025, USD 3.71 billion in 2026, and reach USD 5.28 billion by 2031, growing at a CAGR of 7.31% from 2026 to 2031.

This report is Segmented by Source (Animal-Derived Peptides, Plant-Derived Peptides, and More), Bioactivity (Antihypertensive Peptides, Antioxidant Peptides, and More), Form (Powder, Liquid, Tablets, and More), End User (Food and Beverage Manufacturers, Dietary Supplement Companies, and More), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Value (USD).

Global Bioactive Peptides Market Trends and Insights

Expansion of Functional Foods and Nutraceuticals

The Bioactive Peptides Market benefits as food companies seek sequence-specific ingredients with clinical support. Consumer demand is moving beyond generic protein supplements toward products associated with cardiometabolic, immune, and gut health. A 2025 review reported that food-derived peptides can influence glycemic control through IRS-1/PI3K/Akt activation and AMPK-mediated GLUT4 translocation. The review also described effects involving adipokines, HMG-CoA reductase, and NF-κB/MAPK signaling. These multiple mechanisms allow fortified dairy, beverages, and bars to support more specific health positions. Suppliers that document the mechanism as well as the outcome can support higher-value contracts and longer supply relationships, particularly when branded food companies need evidence that can be used consistently in product development, technical discussions, and consumer-facing health positions.

Rising Demand for Preventive Healthcare and Healthy Aging Solutions

Aging populations in North America, Japan, and Western Europe support demand for peptides used in nutrition for sarcopenia, hypertension, and metabolic decline. A 2025 randomized, double-masked, placebo-controlled study of 114 prehypertensive and hypertensive participants found that HCP-C7C12 reduced systolic blood pressure by 9.41% and diastolic blood pressure by 9.53% over 8 weeks. The study also reported prebiotic-like microbiota effects and activation of pathways associated with butyrate production. This evidence links antihypertensive ingredients to metabolic benefits beyond blood pressure management. The bioactive peptides market, therefore, has a durable health-focused demand base in regions with older populations. ACE inhibition, microbiome effects, and endothelial function give the category relevance across several consumer health needs, allowing a single well-supported ingredient to be considered in products aimed at blood pressure, digestive health, healthy aging, and broader metabolic support.

High Production, Purification and Clinical-Validation Costs

High-purity peptide production remains expensive across the separation, purification, and validation stages. A 2025 review found that high-performance liquid chromatography can achieve the required separation for pharmaceutical-grade purity but has capital and throughput constraints for large food-grade volumes. The review also noted that membrane fouling in ultrafiltration lowers processing efficiency and creates replacement costs. Clinical validation creates another investment requirement for a supplier seeking a supported health claim. These costs favor established ingredient companies that can fund clinical programs and maintain regulatory relationships. The Bioactive Peptides Market can therefore concentrate value among companies with broad portfolios that can support research across product cycles, absorb the cost of unsuccessful programs, and use established commercial relationships to place successful ingredients into multiple food, supplement, and clinical channels.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in Enzymatic Hydrolysis, Purification and Peptide Synthesis
2. AI-Assisted Peptide Discovery and Bioactivity Prediction
3. Stringent Health-Claim, Novel-Food and Ingredient-Approval Requirements

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Animal-Derived Peptides held 42.31% share of global revenue in 2025, supported by established whey, casein, collagen, and gelatin supply chains. Dairy-derived IPP and VPP sequences from fermented milk have clinical evidence base for blood pressure outcomes. The evidence described systolic reductions of 5.0 mm Hg and diastolic reductions of 2.3 mm Hg in clinical meta-analyses. Plant-Derived Peptides are gaining attention from legumes, cereals, and seeds. Chickpea, rapeseed, and hemp proteins have been screened for ACE-inhibitory, DPP-IV-inhibitory, and antioxidant candidate sequences. Animal supply chains remain important because they offer mature raw material availability and established hydrolysis processes. At the same time, dairy and collagen producers can draw on familiar procurement systems, known protein fractions, and existing relationships with food and supplement formulators.

Marine-Derived Peptides use fish skin, bones, viscera, and crustacean shells that would otherwise have lower-value uses. Fish protein hydrolysates can contain 60-90% protein and essential amino acids associated with cardiovascular relevance. Microbial and Fermentation-Derived Peptides offer a separate route using food-grade substrates. Precision fermentation using Lactobacillus and Pediococcus can yield antioxidant, anti-inflammatory, and antidiabetic peptides. Synthetic and Recombinant Peptides represent the fastest-growing source category, with Bioactive Peptides Market size for this segment projected to expand at an 11.58% CAGR through 2031. Pharmaceutical CDMO capacity for solid-phase peptide synthesis supports this growth because investments in equipment, skilled personnel, purification capability, and quality systems can increase the availability of manufacturing resources that are relevant to specialized peptide production. A 2026 review described photocatalysis and electrochemistry as emerging routes that address earlier cost and sustainability limits.

Antihypertensive Peptides led this segment with 34.24% share in 2025. Dairy, marine, and plant sequences are supported by evidence around ACE inhibition and blood pressure outcomes. The Bioactive Peptides Market maintains demand for these products because hypertension has a large preventive-nutrition audience. Fractions below 3 kDa and fractions rich in phenylalanine, tryptophan, and tyrosine showed stronger radical-scavenging activity. Antimicrobial Peptides are also attracting pharmaceutical interest, because the search for new antimicrobial sequences extends beyond conventional bacterial sources and supports investigation of candidates with differentiated biological properties.

A 2025 study identified more than 12,000 putative archaeal antimicrobial peptides through deep-learning prediction. Antidiabetic and DPP-IV-Inhibitory Peptides are the fastest-growing bioactivity category, with the Bioactive Peptides Market size for this segment projected to increase at a 9.22% CAGR through 2031. These peptides can support blood glucose control through CaSR-dependent GLP-1 secretion, DPP-4 inhibition, and inhibition of a-amylase and a-glucosidase. A 2025 review discussed enzymatic hydrolysis, fermentation, and encapsulation methods for placing DPP-IV-inhibitory peptides in functional foods without compromising bioactivity. Immunomodulatory and anti-inflammatory peptides serve the immunity-focused nutrition demand. At the same time, anticancer and neuroprotective sequences remain earlier-stage commercial opportunities that could become more relevant as clinical evidence, delivery systems, and regulatory pathways develop further.

Complete Report Scope:

• By Source
  • Animal-Derived Peptides
  • Plant-Derived Peptides
  • Marine-Derived Peptides
  • Microbial and Fermentation-Derived Peptides
  • Synthetic and Recombinant Peptides
• By Bioactivity and Function
  • Antihypertensive Peptides
  • Antioxidant Peptides
  • Antimicrobial Peptides
  • Anti-Inflammatory Peptides
  • Antidiabetic and DPP-IV-Inhibitory Peptides
  • Immunomodulatory Peptides
  • Others
• By Form
  • Powder
  • Liquid
  • Tablets
  • Capsules
  • Gels, Oral Films and Semi-Solids
  • Other Forms
• By End User
  • Food and Beverage Manufacturers
  • Dietary Supplement Companies
  • Pharmaceutical and Biotechnology Companies
  • Cosmetic and Personal Care Manufacturers
  • Contract Development and Manufacturing Organizations
  • Other End users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 37.61% of the global Bioactive Peptides Market revenue in 2025. High willingness to pay for clinically supported ingredients, mature supplement retail, and established regulatory pathways support this position. A 2024 FDA confirmation allowed Arla Foods Ingredients' whey protein hydrolysates to be used in infant formula for allergy management. This action reflects active regulatory engagement with ingredient innovation. Canada and Mexico are relevant distribution corridors for manufacturers with United States-centered supply chains, since regional production, warehousing, regulatory coordination, and established customer relationships can influence how quickly ingredient suppliers can serve adjacent North American markets.

Europe is a major region where regulation shapes ingredient strategy as strongly as consumer demand. The EU Novel Food pathway under Regulation (EU) 2015/2283 functions as a quality screen and a barrier to entry. The July 2026 authorization of egg membrane hydrolysate gave Eggnovo SL a 5-year exclusivity under the Commission regulation. Collagen peptides are important in the European supplement channel, where GELITA, Weishardt, and Rousselot are major suppliers. Italy and Spain offer growth opportunities for marine-derived peptides due to proximity to fishery by-product streams and European circular-bioeconomy incentives, which can encourage processors to move material from lower-value disposal pathways toward protein recovery, hydrolysis, and specialized functional ingredient uses.

Asia-Pacific has the fastest forecast growth, with the Bioactive Peptides Market size projected to rise at an 8.25% CAGR through 2031. China's functional food sector, India's sports and clinical nutrition demand, and Japan's collagen demand under the FOSHU framework support regional growth. India specializes in cost-efficient solid-phase peptide synthesis, while China is expanding custom synthesis and precision fermentation. GCC demand for halal-certified ingredients supports the Middle East and Africa, while Brazil and Argentina provide soy, marine, and bovine protein inputs in South America. A 2026 review described fermentation and green extraction routes that convert South American agro-industrial coproducts into functional ingredients, indicating that agricultural and processing residues can support ingredient development when producers combine reliable feedstock access with suitable extraction, quality-control, and commercialization systems.

1. Angel Yeast Co., Ltd.
2. Archer Daniels Midland Company
3. Arla Foods Ingredients Group P/S
4. Corden Pharma International
5. Darling Ingredients Inc.
6. dsm-firmenich AG
7. Fonterra Co-operative Group Limited
8. FrieslandCampina Ingredients
9. GELITA AG
10. Genscript
11. Glanbia plc
12. Hilmar Ingredients
13. Ingredia SA
14. Kerry Group plc
15. Nitta Gelatin Inc.
16. Nuritas Limited
17. PolyPeptide Group AG
18. Roquette Freres
19. Rousselot S.A.S.
20. Seagarden AS
21. Weishardt International

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of Functional Foods and Nutraceuticals
  • 4.2.2 Rising Demand for Preventive Healthcare and Healthy Aging Solutions
  • 4.2.3 Growth in Sports Nutrition and Medical Nutrition
  • 4.2.4 Advances in Enzymatic Hydrolysis, Purification and Peptide Synthesis
  • 4.2.5 AI-Assisted Peptide Discovery and Bioactivity Prediction
  • 4.2.6 Upcycling of Dairy, Marine and Agro-Industrial Protein Side Streams
• 4.3 Market Restraints
  • 4.3.1 High Production, Purification and Clinical-Validation Costs
  • 4.3.2 Stringent Health-Claim, Novel-Food and Ingredient-Approval Requirements
  • 4.3.3 Bioactivity Loss Across Processing, Digestion and Storage Conditions
  • 4.3.4 Fragmented Evidence Standards Across Food, Supplement and Pharmaceutical Channels
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Source
  • 5.1.1 Animal-Derived Peptides
  • 5.1.2 Plant-Derived Peptides
  • 5.1.3 Marine-Derived Peptides
  • 5.1.4 Microbial and Fermentation-Derived Peptides
  • 5.1.5 Synthetic and Recombinant Peptides
• 5.2 By Bioactivity and Function
  • 5.2.1 Antihypertensive Peptides
  • 5.2.2 Antioxidant Peptides
  • 5.2.3 Antimicrobial Peptides
  • 5.2.4 Anti-Inflammatory Peptides
  • 5.2.5 Antidiabetic and DPP-IV-Inhibitory Peptides
  • 5.2.6 Immunomodulatory Peptides
  • 5.2.7 Others
• 5.3 By Form
  • 5.3.1 Powder
  • 5.3.2 Liquid
  • 5.3.3 Tablets
  • 5.3.4 Capsules
  • 5.3.5 Gels, Oral Films and Semi-Solids
  • 5.3.6 Other Forms
• 5.4 By End User
  • 5.4.1 Food and Beverage Manufacturers
  • 5.4.2 Dietary Supplement Companies
  • 5.4.3 Pharmaceutical and Biotechnology Companies
  • 5.4.4 Cosmetic and Personal Care Manufacturers
  • 5.4.5 Contract Development and Manufacturing Organizations
  • 5.4.6 Other End users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Angel Yeast Co., Ltd.
  • 6.3.2 Archer Daniels Midland Company
  • 6.3.3 Arla Foods Ingredients Group P/S
  • 6.3.4 CordenPharma International
  • 6.3.5 Darling Ingredients Inc.
  • 6.3.6 dsm-firmenich AG
  • 6.3.7 Fonterra Co-operative Group Limited
  • 6.3.8 FrieslandCampina Ingredients
  • 6.3.9 GELITA AG
  • 6.3.10 GenScript Biotech Corporation
  • 6.3.11 Glanbia plc
  • 6.3.12 Hilmar Ingredients
  • 6.3.13 Ingredia SA
  • 6.3.14 Kerry Group plc
  • 6.3.15 Nitta Gelatin Inc.
  • 6.3.16 Nuritas Limited
  • 6.3.17 PolyPeptide Group AG
  • 6.3.18 Roquette Freres
  • 6.3.19 Rousselot S.A.S.
  • 6.3.20 Seagarden AS
  • 6.3.21 Weishardt International

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment